3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
6
Neuroblastoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Fallopian Tube Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Congenital Abnormalities
1
Interventions
Vincristine
12
Temozolomide
11
Irinotecan
10
Cyclophosphamide
10
Melphalan
8
Filgrastim
8
Etoposide
7
Ifosfamide
6
Granulocyte Colony-Stimulating Factor
6
Doxorubicin
6
Vinorelbine
5
Gemcitabine
5
Busulfan
5
Thiotepa
4
Radiotherapy
4
Peripheral Blood Stem Cell Transplantation
4
Dactinomycin
4
pegfilgrastim
3
liposomal doxorubicin
3
irinotecan sucrosofate
3
fludarabine
3
etoposide phosphate
3
Stem Cell Transplantation
3
Sirolimus
3
Proton Therapy
3
Cisplatin
3
Carboplatin
3
Bone Marrow Transplantation
3
thymoglobulin
2
regorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rhabdomyosarcoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts